Bacterial and cancerous cell membrane fused liposome coordinates with PD-L1 inhibitor for cancer immunotherapy
Graphical Abstract
Abstract
Although tumor cell membranes with broad-spectrum antigens have been explored for cancer vaccines for decades, their relatively poor capacity to stimulate immune responses, especially cellular immune responses, has limited their application. Here, we presented a novel bacterial and cancerous cell membrane fusogenic liposome for co-delivering cell membrane-derived antigens and adjuvants. Meanwhile, a programmed death-ligand 1 (PD-L1) inhibitor, JQ-1, was incorporated into the formulation to tackle the up-regulated PD-L1 expression of antigen-presenting cells (APCs) upon vaccination, thereby augmenting its anti-tumor efficacy. The fusogenic liposomes demonstrated significantly improved cellular uptake by APCs and effectively suppressed PD-L1 expression in bone marrow-derived dendritic cells (BMDCs) in vitro. Following subcutaneous vaccination, the nano-vaccines efficiently drained to the tumor-draining lymph nodes (TDLNs), and significantly inhibited PD-L1 expression of both dendritic cells (DCs) and macrophages within the TDLNs and tumors. As a result, the liposomal vaccine induced robust innate and cellular immune responses and inhibited tumor growth in a colorectal carcinoma-burden mouse model. In summary, the fabricated cell membrane-based fusogenic liposomes offer a safe, effective, and easily applicable strategy for tumor immunotherapy and hold potential for personalized cancer immunotherapy.
Keywords
Electronic Supplementary Material
References
Palucka, K.; Banchereau, J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 2012, 12, 265–277.
Koff, W. C.; Burton, D. R.; Johnson, P. R.; Walker, B. D.; King, C. R.; Nabel, G. J.; Ahmed, R.; Bhan, M. K.; Plotkin, S. A. Accelerating next-generation vaccine development for global disease prevention. Science 2013, 340, 1232910.
Yang, Y. P. Cancer immunotherapy: Harnessing the immune system to battle cancer. J. Clin. Invest. 2015, 125, 3335–3337.
Finn, O. J. Cancer vaccines: Between the idea and the reality. Nat. Rev. Immunol. 2003, 3, 630–641.
Gubin, M. M.; Zhang, X. L.; Schuster, H.; Caron, E.; Ward, J. P.; Noguchi, T.; Ivanova, Y.; Hundal, J.; Arthur, C. D.; Krebber, W. J. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515, 577–581.
Sterner, R. C.; Sterner, R. M. CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J. 2021, 11, 69.
Vandenberk, L.; Belmans, J.; Van Woensel, M.; Riva, M.; Van Gool, S. W. Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines. Front. Immunol. 2016, 6, 663.
González, F. E.; Gleisner, A.; Falcón-Beas, F.; Osorio, F.; López, M. N.; Salazar-Onfray, F. Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum. Vaccin. Immunother. 2014, 10, 3261–3269.
Sloan, J. M.; Kershaw, M. H.; Touloukian, C. E.; Lapointe, R.; Robbins, P. F.; Restifo, N. P.; Hwu, P. MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells. Cancer Gene Ther. 2002, 9, 946–950.
Chiang, C. L. L.; Coukos, G.; Kandalaft, L. E. Whole tumor antigen vaccines: Where are we?. Vaccines 2015, 3, 344–372.
Han, X.; Shen, S. F.; Fan, Q.; Chen, G. J.; Archibong, E.; Dotti, G.; Liu, Z.; Gu, Z.; Wang, C. Red blood cell-derived nanoerythrosome for antigen delivery with enhanced cancer immunotherapy. Sci. Adv. 2019, 5, eaaw6870.
Chen, J.; Jiang, C. C.; Jin, L.; Zhang, X. D. Regulation of PD-L1: A novel role of pro-survival signalling in cancer. Ann. Oncol. 2016, 27, 409–416.
Oh, S. A.; Wu, D. C.; Cheung, J.; Navarro, A.; Xiong, H. Z.; Cubas, R.; Totpal, K.; Chiu, H.; Wu, Y.; Comps-Agrar, L. et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat. Cancer 2020, 1, 681–691.
Tan, K.; Li, R. Z.; Huang, X. T.; Liu, Q. Outer membrane vesicles: Current status and future direction of these novel vaccine adjuvants. Front. Microbiol. 2018, 9, 783.
Schwechheimer, C.; Kuehn, M. J. Outer-membrane vesicles from Gram-negative bacteria: Biogenesis and functions. Nat. Rev. Microbiol. 2015, 13, 605–619.
Wang, S. H.; Gao, J.; Li, M.; Wang, L. G.; Wang, Z. J. A facile approach for development of a vaccine made of bacterial double-layered membrane vesicles (DMVs). Biomaterials 2018, 187, 28–38.
Low, K. B.; Ittensohn, M.; Le, T.; Platt, J.; Sodi, S.; Amoss, M.; Ash, O.; Carmichael, E.; Chakraborty, A.; Fischer, J. et al. Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo. Nat. Biotechnol. 1999, 17, 37–41.
Zhu, H. R.; Bengsch, F.; Svoronos, N.; Rutkowski, M. R.; Bitler, B. G.; Allegrezza, M. J.; Yokoyama, Y.; Kossenkov, A. V.; Bradner, J. E.; Conejo-Garcia, J. R. et al. BET bromodomain inhibition promotes anti-tumor immunity by suppressing PD-L1 expression. Cell Rep. 2016, 16, 2829–2837.
Adeegbe, D. O.; Liu, S. W.; Hattersley, M. M.; Bowden, M.; Zhou, C. W.; Li, S.; Vlahos, R.; Grondine, M.; Dolgalev, I.; Ivanova, E. V. et al. BET bromodomain inhibition cooperates with PD-1 blockade to facilitate antitumor response in Kras-mutant non-small cell lung cancer. Cancer Immunol. Res. 2018, 6, 1234–1245.
Liu, K. S.; Zhou, Z. F.; Gao, H. Y.; Yang, F.; Qian, Y. J.; Jin, H. T.; Guo, Y. M.; Liu, Y.; Li, H. L.; Zhang, C. et al. JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression. Cell Biol. Int. 2019, 43, 642–650.
Andrieu, G. P.; Shafran, J. S.; Smith, C. L.; Belkina, A. C.; Casey, A. N.; Jafari, N.; Denis, G. V. BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response. Cancer Lett. 2019, 465, 45–58.
Willard-Mack, C. L. Normal structure, function, and histology of lymph nodes. Toxicol. Pathol. 2006, 34, 409–424.
Chen, D. S.; Mellman, I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013, 39, 1–10.
Jeanbart, L.; Ballester, M.; de Titta, A.; Corthésy, P.; Romero, P.; Hubbell, J. A.; Swartz, M. A. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. Cancer Immunol. Res. 2014, 2, 436–447.
van Riet, E.; Ainai, A.; Suzuki, T.; Kersten, G.; Hasegawa, H. Combatting infectious diseases; Nanotechnology as a platform for rational vaccine design. Adv. Drug Deliv. Rev. 2014, 74, 28–34.
Jiang, H.; Wang, Q.; Sun, X. Lymph node targeting strategies to improve vaccination efficacy. J. Control. Release 2017, 267, 47–56.
Lutz, M. B.; Kukutsch, N.; Ogilvie, A. L. J.; Rößner, S.; Koch, F.; Romani, N.; Schuler, G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 1999, 223, 77–92.
Qin, M.; Du, G. S.; Qiao, N.; Guo, Z. F.; Jiang, M.; He, C. T.; Bai, S. T.; He, P. H.; Xu, Y. H.; Wang, H. R. et al. Whole-cell-mimicking carrier-free nanovaccines amplify immune responses against cancer and bacterial infection. Adv. Funct. Mater. 2022, 32, 2108917.
Guo, Z. F.; Zhu, Y. N.; Du, G. S.; Qin, M.; He, C. T.; He, P. H.; Song, Y. S.; Chen, W. F.; Bai, S. T.; Wu, F. H. et al. Rapid development of a subunit nano-vaccine against drug-resistant Pseudomonas aeruginosa with effective cross-protection. Nano Today 2022, 43, 101398.
Noh, Y. W.; Kim, S. Y.; Kim, J. E.; Kim, S.; Ryu, J.; Kim, I.; Lee, E.; Um, S. H.; Lim, Y. T. Multifaceted immunomodulatory nanoliposomes: Reshaping tumors into vaccines for enhanced cancer immunotherapy. Adv. Funct. Mater. 2017, 27, 1605398.
Chen, W. F.; Song, Y. S.; Bai, S. T.; He, C. T.; Guo, Z. F.; Zhu, Y. N.; Zhang, Z. R.; Sun, X. Cloaking mesoporous polydopamine with bacterial membrane vesicles to amplify local and systemic antitumor immunity. ACS Nano 2023, 17, 7733–7749.
Marichal, T.; Ohata, K.; Bedoret, D.; Mesnil, C.; Sabatel, C.; Kobiyama, K.; Lekeux, P.; Coban, C.; Akira, S.; Ishii, K. J. et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat. Med. 2011, 17, 996–1002.
McKee, A. S.; Burchill, M. A.; Munks, M. W.; Jin, L.; Kappler, J. W.; Friedman, R. S.; Jacobelli, J.; Marrack, P. Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells. Proc. Natl. Acad. Sci. USA 2013, 110, E1122–E1131.
Flach, T. L.; Ng, G.; Hari, A.; Desrosiers, M. D.; Zhang, P.; Ward, S. M.; Seamone, M. E.; Vilaysane, A.; Mucsi, A. D.; Fong, Y. et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat. Med. 2011, 17, 479–487.
Delgado, M.; Reduta, A.; Sharma, V.; Ganea, D. VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4+ T cells. J. Leucoc. Biol. 2004, 75, 1122–1130.
Orabona, C.; Grohmann, U.; Belladonna, M. L.; Fallarino, F.; Vacca, C.; Bianchi, R.; Bozza, S.; Volpi, C.; Salomon, B. L.; Fioretti, M. C. et al. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat. Immunol. 2004, 5, 1134–1142.
Liu, G. N.; Ma, N. N.; Cheng, K. M.; Feng, Q. Q.; Ma, X. T.; Yue, Y. L.; Li, Y.; Zhang, T. J.; Gao, X. Y.; Liang, J. et al. Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity. Nat. Nanotechnol. 2024, 19, 387–398.
Janes, M. E.; Gottlieb, A. P.; Park, K. S.; Zhao, Z. M.; Mitragotri, S. Cancer vaccines in the clinic. Bioeng. Transl. Med. 2024, 9, e10588.
Cochran, A. J.; Morton, D. L.; Stern, S.; Lana, A. M. A.; Essner, R.; Wen, D. R. Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: Implications for tumor biology and treatment. Mod. Pathol. 2001, 14, 604–608.
Francis, D. M.; Manspeaker, M. P.; Schudel, A.; Sestito, L. F.; O’Melia, M. J.; Kissick, H. T.; Pollack, B. P.; Waller, E. K.; Thomas, S. N. Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. Sci. Transl. Med. 2020, 12, eaay3575.
Fransen, M. F.; Schoonderwoerd, M.; Knopf, P.; Camps, M. G. M.; Hawinkels, L. J. A. C.; Kneilling, M.; van Hall, T.; Ossendorp, F. Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy. JCI Insight 2018, 3, e124507.
Watson, R. A.; Tong, O.; Cooper, R.; Taylor, C. A.; Sharma, P. K.; de Los Aires, A. V.; Mahé, E. A.; Ruffieux, H.; Nassiri, I.; Middleton, M. R. et al. Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8+ T cell clone size and cytotoxicity. Sci. Immunol. 2021, 6, eabj8825.
Horton, B. L.; Morgan, D. M.; Momin, N.; Zagorulya, M.; Torres-Mejia, E.; Bhandarkar, V.; Wittrup, K. D.; Love, J. C.; Spranger, S. Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer. Sci. Immunol. 2021, 6, eabi8800.
Gupta, R. K. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 1998, 32, 155–172.
Low, K. B.; Ittensohn, M.; Luo, X.; Zheng, L. M.; King, I.; Pawelek, J. M.; Bermudes, D. Construction of VNP20009: A novel, genetically stable antibiotic-sensitive strain of tumor-targeting Salmonella for parenteral administration in humans. Methods Mol. Med. 2004, 90, 47–60.
Broadway, K. M.; Scharf, B. E. Salmonella typhimurium as an anticancer therapy: Recent advances and perspectives. Curr. Clin. Microbiol. Rep. 2019, 6, 225–239.
Chen, W. F.; Zhu, Y. N.; Zhang, Z. R.; Sun, X. Advances in Salmonella typhimurium-based drug delivery system for cancer therapy. Adv. Drug Deliv. Rev. 2022, 185, 114295.
Clairmont, C.; Lee, K. C.; Pike, J.; Ittensohn, M.; Low, K. B.; Pawelek, J.; Bermudes, D.; Brecher, S. M.; Margitich, D.; Turnier, J. et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimuvium. J. Infect. Dis. 2000, 181, 1996–2002.
京公网安备11010802044758号